An AI Scientist Proposed an ADHD Treatment on the Blockchain: BIO Price Surges
Key Takeaways:
- Bio Protocol’s crypto has soared 90% following a $6.9M funding boost for its AI-native platform, Bio V2.
- The funding was led by Maelstrom Fund and aims to facilitate onchain fundraising and autonomous AI co-scientists.
- Bio Protocol’s scientific proposal for an ADHD treatment targeting orexin receptors drove excitement in crypto-science circles.
- BIO’s recent price spike of 40% from a low-liquidity range highlights volatility in DeSci investments.
- LiquidChain is developing cross-chain infrastructure to support emerging DeSci and DeFi applications.
WEEX Crypto News, 2026-04-17 07:14:58
Decentralized Science and BIO Crypto’s Surge
Bio Protocol crypto recently experienced a staggering 90% price increase, catalyzed by substantial funding advancements and innovative AI applications. With a $6.9 million financial injection from Maelstrom Fund, Bio V2—a full-stack AI-native platform—was positioned at the forefront, promising onchain fundraising capabilities and AI-driven co-scientists, known as BioAgents. This development is a significant step forward in decentralized science (DeSci), capturing the focus of traders and scientists alike.
The spotlight shone further as Bio Protocol’s scientific team proposed a peptide targeting ADHD, sparking interest across crypto-science communities. Studies have shown that ADHD patients have lower levels of orexin-A/B, key in regulating arousal and attention. While existing treatments suppress orexin activity, Bio Protocol and @peptai_ have developed a peptide labeled OX2R-004, aiming to activate the OX2R receptor—potentially redefining ADHD treatment.
Can Bio Protocol Maintain Its Bullish Momentum?
Bio Protocol’s bold 40% price surge emerged from a low-liquidity environment, typifying DeSci’s high volatility. This sudden leap, while exciting, lacked a firm technical foundation, leading to questions about whether the spike can be sustained or will retract. Such moves are often followed by a period of consolidation or a partial pullback, determined by the balance between hype-driven interests and tangible utility.
Currently, BIO finds itself at an intersection between heightened interest and practical utility. To ensure a lasting price escalation, demand must translate into real-world usage, sustaining momentum as the narrative surpasses mere speculation. However, if Bio V2 fails to deliver measurable impact, the price may revert to its pre-announcement level. The broader crypto market also plays a role; downward trends in related tokens could influence BIO, potentially triggering a broader decline.
The Role of LiquidChain in DeSci’s Growth
LiquidChain has emerged as a potential game-changer in bridging the gap between decentralized science and decentralized finance applications. It’s constructing a Layer 3 protocol that combines Bitcoin’s financial strength, Ethereum’s DeFi capabilities, and Solana’s execution speed into a single, cohesive liquidity environment, without the need for asset wrapping. This innovation is key to supporting multi-chain DeSci initiatives.
LiquidChain’s architecture enables developers to create applications once and tap into user bases across multiple ecosystems—an attractive proposition for DeSci and DeFi projects. As of now, $674,947.04 has been raised in its presale, with tokens priced at $0.0145. However, presales harbor risks; success hinges on broader adoption rates, while premature entries have diminishing returns once catalysts are publicly realized.
FAQ Section
What caused Bio Protocol’s price to surge by 90%?
Bio Protocol’s price increased due to a $6.9 million funding round for its AI-native platform, Bio V2, backed by Maelstrom Fund. This elevated efforts for onchain fundraising and the involvement of AI co-scientists, attracting significant interest.
Is Bio Protocol’s ADHD treatment scientifically promising?
Bio Protocol’s ADHD treatment focuses on activating the OX2R receptor with a peptide, OX2R-004. This contrasts current treatments which suppress orexin activity, offering a scientifically provocative approach to ADHD.
Can Bio Protocol sustain its current price level?
To maintain its price, Bio Protocol needs continuous demand linked to practical usage and proven utility of its platform. Hype alone can cause the price to revert once interest wanes.
What does LiquidChain offer to DeSci and DeFi projects?
LiquidChain facilitates a unified liquidity environment across blockchain ecosystems—Bitcoin, Ethereum, and Solana—thereby supporting DeSci and DeFi applications through its deploy-once framework without asset wrapping.
Are there risks associated with investing in LiquidChain’s presale?
LiquidChain’s presale carries risks, particularly due to adoption uncertainties. The potential for low initial market listings and reliance on sustained infrastructure integration poses investment challenges.
You may also like

Morning Report | Former Ethereum Foundation researcher establishes Ethlabs; EU Parliament Economic Committee passes digital euro regulatory proposal

Interview with NDV Founder Jason Huang: Popping the AI Bubble and the Myth of Microstrategy, Seeking the Ultimate Ace in the Crypto Market

Morning Report | The South Korean Financial Services Commission plans to expand the regulatory sandbox to include virtual assets; the parent company of the New York Stock Exchange, ICE, has reached a partnership with OKX to jointly establish a cryptocu...

Exclusive Interview with Strategy CEO: Putting Aside the Sale of 32 BTC, the 60 Trillion AI Intelligence is the Ultimate Fate of Bitcoin

TRON revitalizes the image of the bull, creating a more approachable brand character

Will the STRC issuance price discussed with ChatGPT really fall into a death spiral?

The foundation retreats, Ethlabs steps forward: Ethereum welcomes its largest restructuring in history

NYSE Parent ICE and OKX Launch Joint Venture: What It Means for Tokenized Stocks
ICE and OKX have announced a joint venture focused on tokenized stocks, but stock futures are already live across crypto markets. Here's what the partnership means, how stock futures work, and why traders are paying attention.
How to Trade Apple and Nvidia on a Crypto Exchange in 2026 (Without Buying Shares)

Morning Report | Secret Network loses $4.67 million due to cross-chain vulnerability; Michael Saylor releases Bitcoin Tracker information again, may disclose increased holdings data next week

Kalshi's biggest competitor is not Polymarket

The second half of the computing power battle: Intel CEO Pat Gelsinger reveals how AI is reshaping the global semiconductor supply chain

B.AI partners with MiniMax to launch a limited-time free experience of M3, enabling zero-threshold implementation of Agentic productivity through full-stack infrastructure

A company that was on the verge of bankruptcy has just surpassed Bitcoin in market value

The two giants are racing in "credit": loan balances of 9.9 billion vs 14.6 billion USD, Brazil has become the main battlefield

Rented Belief: How Much of the Bitcoin ETF Fund Flow is Real Money

On-chain finance: On-chain IPOs and on-chain ICOs, a new frontier in the trillion-dollar market


